GAD2

Across TCGA pan-cancer cohorts, GAD2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GAD2 data layer compared with 18 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GAD2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GAD2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC and GBM are the cancer types where GAD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.328	0.548	.025	6	view →
GBM	DFS	Median	All	0.852	0.649	.012	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

GAD2–PDAC (OS)

Open the PDAC breakdown →